245 related articles for article (PubMed ID: 24219039)
21. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
22. Modern treatment strategies in rheumatoid arthritis.
Hetland ML
Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
[TBL] [Abstract][Full Text] [Related]
23. The use of conventional disease-modifying anti-rheumatic drugs in established RA.
Jurgens MS; Jacobs JW; Bijlsma JW
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):523-33. PubMed ID: 22137922
[TBL] [Abstract][Full Text] [Related]
24. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
Pincus T
Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
[TBL] [Abstract][Full Text] [Related]
25. Outcome of patients with rheumatoid arthritis: cross-sectional study of a single-center real-world inception cohort.
Ling E; Ofer-Shiber S; Goren O; Molad Y
Isr Med Assoc J; 2013 Dec; 15(12):758-62. PubMed ID: 24449980
[TBL] [Abstract][Full Text] [Related]
26. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
27. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.
van Tuyl LH; Lems WF; Voskuyl AE; Kerstens PJ; Garnero P; Dijkmans BA; Boers M
Ann Rheum Dis; 2008 Nov; 67(11):1574-7. PubMed ID: 18625629
[TBL] [Abstract][Full Text] [Related]
28. Lessons for the use of non-biologic anchor treatments for rheumatoid arthritis in the era of biologic therapies.
Jacobs JW
Rheumatology (Oxford); 2012 Jun; 51 Suppl 4():iv27-33. PubMed ID: 22685273
[TBL] [Abstract][Full Text] [Related]
29. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007?
Yazici Y; Abramson SB
Bull NYU Hosp Jt Dis; 2007; 65(4):300-5. PubMed ID: 18081549
[TBL] [Abstract][Full Text] [Related]
30. Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study.
Mandl P; Balint PV; Brault Y; Backhaus M; D'Agostino MA; Grassi W; van der Heijde D; de Miguel E; Wakefield RJ; Logeart I; Dougados M
Arthritis Care Res (Hoboken); 2013 Jun; 65(6):879-87. PubMed ID: 23213004
[TBL] [Abstract][Full Text] [Related]
31. Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies.
van der Woude D; Visser K; Klarenbeek NB; Ronday HK; Peeters AJ; Kerstens PJ; Dijkmans BA; Huizinga TW; van der Helm-van Mil AH; Allaart CF
Rheumatology (Oxford); 2012 Jun; 51(6):1120-8. PubMed ID: 22337939
[TBL] [Abstract][Full Text] [Related]
32. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
Allaart CF; Breedveld FC; Dijkmans BA
J Rheumatol Suppl; 2007 Nov; 80():25-33. PubMed ID: 17985420
[TBL] [Abstract][Full Text] [Related]
33. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
34. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
Verschueren P; Esselens G; Westhovens R
Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
[TBL] [Abstract][Full Text] [Related]
35. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
36. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
Caporali R; Scirè CA; Todoerti M; Montecucco C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
[TBL] [Abstract][Full Text] [Related]
37. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
Nandi P; Kingsley GH; Scott DL
Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
[TBL] [Abstract][Full Text] [Related]
38. Treat to target strategy in rheumatoid arthritis: real benefits.
Cardiel MH
Reumatol Clin; 2013; 9(2):101-5. PubMed ID: 22985804
[TBL] [Abstract][Full Text] [Related]
39. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
Swierkot J; Madej M
Pol Merkur Lekarski; 2011 Apr; 30(178):283-8. PubMed ID: 21595176
[TBL] [Abstract][Full Text] [Related]
40. Overview and analysis of treat-to-target trials in rheumatoid arthritis reporting on remission.
Jurgens MS; Welsing PM; Jacobs JW
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S56-63. PubMed ID: 23078808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
